OPKO and Entera Bio partner on oral obesity treatment

MIAMI and JERUSALEM - OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) have announced a collaboration to develop an oral treatment for obesity and other metabolic disorders. Entera Bio, with a current market capitalization of $69.24 million, brings strong financial fundamentals to the partnership, maintaining more cash than debt on its balance sheet. The companies plan to advance into clinical trials with an oral dual agonist GLP-1/glucagon peptide, a once-daily tablet designed to treat patients with obesity, metabolic, and fibrotic disorders.